Scarica l'app Stockscreener
31.96
2.34%
0.73
Pre-mercato:
32.50
0.54
+1.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.23
Aprire:
$31.2
Volume 24 ore:
4.47M
Relative Volume:
2.95
Capitalizzazione di mercato:
$5.41B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
16.39
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
+2.11%
1M Prestazione:
+13.82%
6M Prestazione:
+22.59%
1 anno Prestazione:
+16.98%
Intervallo 1D:
$31.05
$32.03
Intervallo di 1 settimana:
$31.00
$32.03
Portata 52W:
$22.90
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Confronta ALKS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
31.96 | 5.41B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
174.29 | 78.63B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.85 | 44.54B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 42.61B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 18.79B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
127.56 | 13.55B | 612.78M | -86.37M | -62.91M | -0.87 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Earnings To Watch: Alkermes PLC (ALKS) Reports Q4 2024 Result - GuruFocus.com
Alkermes plc (NASDAQ:ALKS) Shares Sold by abrdn plc - MarketBeat
Deutsche Bank Aktiengesellschaft Begins Coverage on Alkermes (NASDAQ:ALKS) - MarketBeat
Deutsche Bank sets Alkermes stock Buy rating, $40 target By Investing.com - Investing.com UK
What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings - Yahoo Finance
Nanotechnology Drug Delivery Market Size to Reach USD 203.21 - openPR
Hypersomnia Pipeline 2024: MOA, ROA, and Clinical Trial - openPR
Robeco Institutional Asset Management B.V. Buys 26,980 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 - GuruFocus.com
FY2027 EPS Estimates for Alkermes Lifted by Leerink Partnrs - MarketBeat
Trading (ALKS) With Integrated Risk Controls - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) EVP Sells $3,234,421.90 in Stock - MarketBeat
Alkermes plc (NASDAQ:ALKS) Sees Large Decline in Short Interest - MarketBeat
BofA Adjusts Price Target on Alkermes Public to $33 From $31 -February 03, 2025 at 10:16 am EST - Marketscreener.com
FY2025 EPS Estimates for Alkermes Lowered by Leerink Partnrs - MarketBeat
Alkermes FY2027 EPS Forecast Increased by Leerink Partnrs - Defense World
FY2025 EPS Estimates for Alkermes Reduced by Leerink Partnrs - Defense World
Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Jefferies maintains Buy on Alkermes stock, target at $41 By Investing.com - Investing.com UK
Pacer Advisors Inc. Decreases Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes Wide Awake To Blockbuster Narcolepsy Market Potential - Citeline News & Insights
Alkermes Plc to Host Earnings Call - ACCESS Newswire
Alkermes (NASDAQ:ALKS) Trading Up 5.4%Still a Buy? - MarketBeat
(ALKS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
With nearly $1B in the bank, Alkermes is on the hunt for deals - The Business Journals
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 14.1% - MarketBeat
Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price - Simply Wall St
(ALKS) Proactive Strategies - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Holdings Trimmed by JPMorgan Chase & Co. - MarketBeat
FY2024 EPS Estimates for Alkermes Lowered by Zacks Research - Defense World
Zacks Research Reduces Earnings Estimates for Alkermes - MarketBeat
What is Zacks Research's Forecast for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc (NASDAQ:ALKS) Receives $36.00 Average PT from Brokerages - MarketBeat
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Alkermes to Report Third Quarter Financial Results on October 24, 2024 - Quantisnow
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)? - Yahoo Finance
Alkermes plc (NASDAQ:ALKS) Sees Large Decrease in Short Interest - MarketBeat
Principal Financial Group Inc. Has $24.57 Million Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
(ALKS) On The My Stocks Page - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Stake Boosted by Sanctuary Advisors LLC - MarketBeat
Expansion Therapeutics Names Elliot Ehrich, MD, Chief Medical Officer - Marketscreener.com
Alkermes pays off and terminates major credit agreement By Investing.com - Investing.com Canada
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
Alkermes pays off and terminates major credit agreement - Investing.com
Alkermes Prepares for New Flexibility Post Credit Termination - TipRanks
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.61%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):